# A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

> **NCT02185690** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 13 (actual)

## Conditions studied

- Lungcancer

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02185690
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2019-07-04
- **Final completion:** 2019-07-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185690, "A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02185690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*